Kyle W. Sloop - Concepedia

Author

Kyle W. Sloop

Also Known As

K Sloop, K. W. SLOOP, K. W. Sloop, K.W. Sloop, KYLE SLOOP, KYLE W. SLOOP, Kyle Sloop, Kyle W Sloop, Kyle W. Sloop, Kyle W. Sloop

138

Publications

7.2K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Indiana University – Purdue University Indianapolis University of Indianapolis Ionis Pharmaceuticals (United States)University of Toronto

About

Kyle W. Sloop is an author at Eli Lilly (United States) specializing in medicine, endocrinology, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	30	1.9K
2	Health Sciences	10	10	1.1K
3	Natural Sciences	5	5	152
4	Public Health	1	1	12
5	Social Sciences	1	1	59

Kyle W. Sloop

Publications

6.2K

Citations

H-Index

Page 1

	Year	Citations
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept Tamer Coşkun, Kyle W. Sloop, Corina Loghin, Molecular Metabolism	2018	766
Regulation of Expression of ob mRNA and Protein by Glucocorticoids and cAMP Lawrence J. Slieker, Kyle W. Sloop, Peggy L. Surface, Journal of Biological Chemistry	1996	479
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist Francis S. Willard, Jonathan D. Douros, M Gabe, JCI Insight PharmacotherapyExperimental PharmacologyInsulin SignalingObesityMolecular Pharmacology	2020	439
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Tamer Coşkun, Shweta Urva, William C. Roell, Cell Metabolism	2022	246
Hepatic and glucagon-like peptide-1–mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors Kyle W. Sloop, Julia X.C. Cao, Angela M. Siesky, Journal of Clinical Investigation	2004	210
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice Ricardo J. Samms, Michael E. Christe, Kyla Collins, Journal of Clinical Investigation	2021	204
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist Takahiro Kawai, Bingfa Sun, Hitoshi Yoshino, Proceedings of the National Academy of Sciences	2020	172
Activation of the GLP-1 receptor by a non-peptidic agonist Peishen Zhao, Yi-Lynn Liang, Matthew J. Belousoff, Nature Molecular PharmacologyMolecular PhysiologySignal TransductionG Protein-coupled ReceptorMedicine	2020	167
The Furan Fatty Acid Metabolite CMPF Is Elevated in Diabetes and Induces β Cell Dysfunction Kacey J. Prentice, Lemieux Luu, Emma M. Allister, Cell Metabolism Metabolic SyndromeBiochemistryPhysiologyDiabetesMetabolic Regulation	2014	154
Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides Merrill D. Benson, Barbara Kluve‐Beckerman, Steven R. Zeldenrust, Muscle & Nerve	2006	146

Page 1